Neonatal hyperbilirubinemia

Itoh S, et al. Phototherapy for neonatal hyperbilirubinemia. Pediatr Int. 2017 May 31.

About 60 years ago in England, phototherapy for neonatal hyperbilirubinemia was actually used in clinical practice. It was introduced in Japan about 50 years ago. However, the mechanism of how the serum bilirubin concentration was decreased by the phototherapy was still unknown. The mechanism was identified by chemists, biochemists, and pediatricians. Clarification started with the report that unconjugated bilirubin was excreted into bile after the photoirradiation of Gunn rats. After the molecular conformation of bilirubin by X-ray analysis, the mechanism for bile excretion of unconjugated bilirubin was verified based on geometric configurational photoisomers in the Gunn rat. Finally, the reaction and excretion of structural bilirubin photoisomers was proved to be the main mechanism for the decrease in serum bilirubin during phototherapy for neonatal hyperbilirubinemina, which differs from the mechanism in the Gunn rat. However, the most effective and safest light source and the optimal method to evaluate phototherapy remain unknown. Moreover, as for bronze baby syndrome which is a well-known adverse reaction to phototherapy, the substances as the etiological origin are unclear. Hence, we review phototherapy for hyperbilirubinemia including a fundamental understanding of the bilirubin photochemical reactions, and discuss the subclinical carcinogenic risk of phototherapy and the increased mortality rate of extremely very low birth weight infants due to aggressive phototherapy, which is becoming a problem an increasing.

Full-text for Emory users.

Maisels MJ. Managing the jaundiced newborn: a persistent challenge. CMAJ. 2015
Mar 17;187(5):335-43.

“In this review, I present an approach to managing the jaundiced newborn that is based on published guidelines. [2-5] The aim is to help clinicians identify and manage jaundice in the newborn, intervene when appropriate and, when possible, prevent bilirubin-induced brain damage. It would be ideal if the published guidelines for the management of hyperbilirubinemia, including treatment with phototherapy and exchange transfusion, were based on estimates of when the benefit of these interventions exceeded their risks and costs. These estimates should come from randomized trials or high-quality, systematic observational studies, but such studies are rare. Guidelines must therefore rely on relatively uncertain estimates of risk and benefits, often from conflicting results.”

Full-text for Emory users.

Continue reading